While the emergence of immune checkpoint inhibitors has improved cancer patient outcomes, efficacy in high-grade serous ovarian cancer (HGSOC) is limited. Here, the authors report a phase 2 clinical trial investigating immune activation and efficacy of neoadjuvant pembrolizumab administered after one cycle of neo-adjuvant chemotherapy in patients with untreated stage IV HGSOC.
- S. L. Aronson
- B. Thijssen
- G. S. Sonke
